Table 1.
Sociodemographics and clinical characteristics of participants with a history of cardiovascular disease from the ISCOPE study (n = 1350).
| n (%) | |
| Sociodemographic | |
| Age in years (median (interquartile range)) | 81 (78–85) |
| Male | 678 (50) |
| GPs’ judgement of vulnerability1 | |
| Vulnerable | 411 (30) |
| Possibly or not vulnerable | 927 (69) |
| Cardiovascular disease history2 | |
| Severity | |
| Minor cardiovascular disease3 | 619 (46) |
| Major cardiovascular disease4 | 731 (54) |
| Type of vascular bed | |
| Cardiac | 834 (62) |
| Angina | 428 (32) |
| Myocardial infarction | 377 (28) |
| Ischaemic heart disease | 122 (9) |
| Cerebral | 494 (37) |
| Transient ischaemic attack | 246 (18) |
| Stroke | 257 (19) |
| Peripheral | 253 (19) |
| Intermittent claudication | 195 (14) |
| Aneurysm | 68 (5) |
| Cardiovascular preventive treatment with lipid-lowering or antithrombotic drugs | |
| Type | |
| Lipid-lowering drug5 | 733 (54) |
| Antithrombotic drugs (aspirin or oral anticoagulant) | 1050 (78) |
| Completeness of treatment | |
| Optimal treatment: both lipid-lowering drug and antithrombotic drug6 | 680 (50) |
| Suboptimal treatment: lipid-lowering drug only | 53 (4) |
| Suboptimal treatment: anti-thrombotic drug only | 370 (27) |
| Poor treatment: no lipid-lowering or antithrombotic drug | 247 (18) |
1Assessed before screening (12 missing values); vulnerable participants versus possibly vulnerable (n = 360), not vulnerable (n = 513), or don’t know (n = 54); 2obtained from EMR general practitioners; 3history of angina, transient ischaemic attack, or intermittent claudication; 4history of myocardial infarction, stroke, or arterial surgery; 5use of statins (n = 1336) or other lipid-lowering drugs (n = 14); 6use of both drugs for more than 270 days during the first year of the ISCOPE study.